NET-02: a multi-center, randomised, phase II trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC)
McNamara, Mairead G Swain, J Craig, Z Wadsley, J Reed, N Faluyi, OO Lamarca, Angela Hubner, Richard A Mansoor, Was Sarker, D
McNamara, Mairead G
Swain, J
Craig, Z
Wadsley, J
Reed, N
Faluyi, OO
Lamarca, Angela
Hubner, Richard A
Mansoor, Was
Sarker, D
Citations
Altmetric:
Abstract
Description
Date
2019
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
McNamara MG, Swain J, Craig Z, Wadsley J, Reed N, Faluyi OO, et al. NET-02: a multi-center, randomised, phase II trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC). J Clin Oncol. 2019;37(15_suppl):TPS4158-TPS.